FOLLOW THE MONEY

The proposed “Pandemic Treaty” is not about health. It's a business plan to redistribute wealth on a global scale. It offers a financial windfall for Big Pharma. Cui Bono? WHO benefits? The WHO does!

Please watch the video below…

The proposed “Pandemic Treaty” is NOT about your health.

The proposed “Pandemic Treaty” is about MONEY.

The proposed “Pandemic Treaty” is about the re-distribution of wealth on a global scale.

The following excerpts are from the proposed “Zero Draft.”

https://apps.who.int/gb/inb/pdf_files/inb4/A_INB4_3-en.pdf

The (numbers in parentheses) in the list below refer to the legally binding-requirements in the proposed “Pandemic Treaty” that are detailed further below in this article.

These excerpts are about money and finance, NOT HEALTH.

1. The WHO Global Pandemic Supply Chain and Logistics Network (2)

2. maintaining strategic stockpiles (3)

3. relevant stakeholders (3)

4. sources of, manufacturers and suppliers (4)

5. sustainable production of pandemic-related products (4)

6. especially active pharmaceutical ingredients (4)

7. regional purchasing mechanisms (4)

8. in-kind contributions (4)

9. existing delivery and distribution options (6)

10. international consolidation hubs (6)

11. regional staging areas (6)

12. a dashboard for pandemic-related product supply capacity and availability (7)

13. conduct regular tabletop exercises (7)

14. The Parties COMMIT not to impose regulations that unduly interfere with the trade in, or of, pharmaceutical raw materials and ingredients (8)

15. unhindered access to pandemic-related products (8)

16. incentivize manufacturers of pandemic-related products to transfer relevant technology and know-how to capable manufacturer(s) (11)

17. technology transfer hubs (11)

18. product development partnerships (11)

19. intellectual property and trade (12)

20. mapping manufacturing capacities and demand (12)

21. licenses to capable manufacturers… to use their intellectual property and other protected substances, products, technology, know-how, information and knowledge used in the process of pandemic response product research, development and production, in particular for pre-pandemic and pandemic-related products (13)

22. support time-bound waivers of intellectual property rights that can accelerate or scale up manufacturing of pandemic-related products during a pandemic (15)

23. accelerate the process of approving and licensing pandemic-related products for emergency use (20)

24. promote and incentivize technology co-creation and joint venture initiatives (25)

25. distributed manufacturing, licensing, technology transfer and pricing policies (26)

26. ensuring that these measures do not create any unnecessary administrative hurdles for research (33)

27. ensuring equitable access to resources (funding or in-kind) (35)

28. Pathogen Access and Benefit-Sharing System (PABS) System (38)

29. The PABS System SHALL cover all pathogens with pandemic potential, including their genomic sequences, as well as access to benefits arising therefrom (39)

30. provide pathogens with pandemic potential from early infections due to pathogens with pandemic potential or subsequent variants to a laboratory recognized or designated as part of an established WHO coordinated laboratory network (40)

31. upload the genomic sequence of such pathogens with pandemic potential to one or more publicly accessible databases of its choice (41)

32. Access SHALL be accorded expeditiously by the laboratory recognized or designated as part of an established WHO coordinated laboratory network (42)

33. Recipients of materials SHALL NOT claim any intellectual property or other rights (43)

34. Benefit-sharing options available to entities accessing pathogens with pandemic potential (46)

35. real-time access by WHO to 20% of the production of safe, efficacious and effective pandemic-related products, including diagnostics, vaccines, personal protective equipment and therapeutics (47)

36. The pandemic-related products SHALL be provided to WHO on the following basis: 10% as a donation and 10% at affordable prices to WHO; (48)

37. Commitments by the countries where manufacturing facilities are located that they WILL facilitate the shipment to WHO of these pandemic-related products by the manufacturers within their jurisdiction, according to schedules to be agreed between WHO and manufacturers. (48)

38. Development and operationalization of the PABS System… including through sustaining it in inter-pandemic times (50)

39. The Parties WILL convene multi-country or regional tabletop exercises every two years (67)

40. facilitate WHO with rapid access to outbreak areas within the Party’s jurisdiction or control, including through the deployment of rapid response and expert teams, to assess and support the response to emerging outbreaks. (79)

41. Raise financial resources for effective implementation of the WHO CA+ through bilateral and multilateral funding mechanisms (96)

42. Domestic funding… not lower than 5% of its current health expenditure to pandemic prevention, preparedness, response and health systems recovery (98)

43. each Party SHALL: (d) commit to allocate.. XX% of its gross domestic product for international cooperation and assistance on pandemic prevention, preparedness, response and health systems recovery (99)

44. Provide funding for the development and strengthening of pandemic prevention, preparedness, response and health system recovery programmes of developing country Parties (101)

45. Facilitate rapid and effective mobilization of adequate financial resources, including from international financing facilities (102)

46. The Parties represented in relevant regional and international intergovernmental organizations and financial and development institutions SHALL encourage these entities to provide financial assistance for developing country Parties to support them in meeting their obligations under the WHO CA+ (103)

47. Each Party to the WHO CA+ SHALL have one vote [regardless of how much money they contribute] (105)

How much money do you think Big Pharma is going to extract from the nations that agree to become “parties” to the proposed “Pandemic Treaty?”

---

BIG PHARMA

https://www.bitchute.com/video/AoTuksjRTBsN/

LEGALLY-BINDING TREATY OBLIGATIONS

If your “Public Servant” insists that the proposed “Pandemic Treaty” is NOT going to be “legally-binding,” please share the list below with them in order to help raise their awareness of reality.

Within THE ZERO DRAFT, the words “shall,” “commit” and “will” appear over 100 times. The 100+ items listed below are direct quotes from THE ZERO DRAFT.

https://apps.who.int/gb/inb/pdf_files/inb4/A_INB4_3-en.pdf

In law, the words “shall,” “commit” and “will” indicate that the nations who become “parties” to the proposed “Pandemic Treaty” will have agreed to REDISTRIBUTE WEALTH in the following ways:

1. All Parties SHALL cooperate with other States and relevant international organizations, in order to collectively strengthen, support and sustain capacities for global prevention, preparedness, response and recovery of health systems. (page 11)

2. The WHO Global Pandemic Supply Chain and Logistics Network (the “Network”) is hereby established. The Parties SHALL support the Network’s development and operationalization, and participate in the Network, within the framework of WHO, including through sustaining it in inter-pandemic times as well as appropriate scale-up in the event of a pandemic. (page 13)

3. The Parties SHALL: (a) determine the types and size of products needed for robust pandemic prevention, preparedness and response, including costs and logistics for establishing and maintaining strategic stockpiles of such products, by working with relevant stakeholders and experts, guided by scientific evidence and regular epidemiological risk assessments; (page 13)

4. The Parties SHALL: (b) assess anticipated demand for, and map sources of, manufacturers and suppliers, including raw materials and other necessary inputs, for sustainable production of pandemic-related products (especially active pharmaceutical ingredients), including manufacturing capacities, and identify the most efficient multilateral and regional purchasing mechanisms, including pooled mechanisms and in-kind contributions, as well as promoting transparency in cost and pricing of all elements along the supply chain; (page 13)

5. The Parties SHALL: (c) develop a mechanism to ensure the fair and equitable allocation of pandemic-related products based on public health risks and needs; (page 13)

6. The Parties SHALL: (d) map existing delivery and distribution options, and establish or operationalize, as appropriate, international consolidation hubs, as well as regional staging areas, to ensure that transport of supplies is streamlined and uses the most appropriate means for the products concerned; (page 13)

7. The Parties SHALL: (e) develop a dashboard for pandemic-related product supply capacity and availability, with regular reporting, and conduct regular tabletop exercises to test the functioning of the Network. (page 13)

8. The Parties COMMIT not to impose regulations that unduly interfere with the trade in, or of, pharmaceutical raw materials and ingredients, mindful of the need for unhindered access to pandemic-related products. (page 13)

9. The Parties COMMIT to safeguard the humanitarian principles of humanity, neutrality, impartiality and independence, and to facilitate the unimpeded access of humanitarian staff and cargo. The COMMITMENT to facilitate such access is understood to be LEGALLY BINDING and to apply in all circumstances, consistent with humanitarian principles. (page 14)

10. The Parties, working through the Governing Body for the WHO CA+, SHALL take all appropriate measures to establish and start functioning of the Network no later than XX. It is understood that giving effect to this Article immediately upon adoption of the WHO CA+ shall be considered pursuant to, and within the meaning of, Article 35 of the WHO CA+. (page 14)

11. During inter-pandemic times, all Parties COMMIT to establish these mechanisms and SHALL: (a) coordinate, collaborate, facilitate and incentivize manufacturers of pandemic-related products to transfer relevant technology and know-how to capable manufacturer(s) (as defined below) on mutually agreed terms, including through technology transfer hubs and product development partnerships, and to address the needs to develop new pandemic-related products in a short time frame; (page 14)

12. During inter-pandemic times, all Parties COMMIT to establish these mechanisms and SHALL: (b) strengthen coordination, with relevant international organizations, including United Nations agencies, on issues related to public health, intellectual property and trade, including timely matching of supply to demand and mapping manufacturing capacities and demand; (page 14)

13. During inter-pandemic times, all Parties COMMIT to establish these mechanisms and SHALL: (c) encourage entities, including manufacturers within their respective jurisdictions, that conduct research and development of pre-pandemic and pandemic-related products, in particular those that receive significant public financing for that purpose, to grant, on mutually agreed terms, licenses to capable manufacturers, notably from developing countries, to use their intellectual property and other protected substances, products, technology, know-how, information and knowledge used in the process of pandemic response product research, development and production, in particular for pre-pandemic and pandemic-related products; (page 14)

14. During inter-pandemic times, all Parties COMMIT to establish these mechanisms and SHALL: (d) collaborate to ensure equitable and affordable access to health technologies that promote the strengthening of national health systems and mitigate social inequalities. (page 14)

15. In the event of a pandemic, the Parties: (a) WILL take appropriate measures to support time-bound waivers of intellectual property rights that can accelerate or scale up manufacturing of pandemic-related products during a pandemic, to the extent necessary to increase the availability and adequacy of affordable pandemic-related products; (page 14)

16. In the event of a pandemic, the Parties: (b) WILL apply the full use of the flexibilities provided in the TRIPS Agreement, including those recognized in the Doha Declaration on the TRIPS Agreement and Public Health of 2001 and in Articles 27, 30 (including the research exception and “Bolar” provision), 31 and 31bis of the TRIPS Agreement; (page 15)

17. ****In the event of a pandemic, the Parties: (c) SHALL encourage all holders of patents related to the production of pandemic-related products to waive, or manage as appropriate, payment of royalties by developing country manufacturers on the use, during the pandemic, of their technology for production of pandemic related products, and shall require, as appropriate, those that have received public financing for the development of pandemic-related products to do so; (page 15)

18. ****In the event of a pandemic, the Parties: (d) SHALL encourage all research and development institutes, including manufacturers, in particular those receiving significant public financing, to waive, or manage as appropriate, royalties on the continued use of their technology for production of pandemic-related products. (page 15)

19. The Parties SHALL strengthen the capacity and performance of national regulatory authorities and increase the harmonization of regulatory requirements at the international and regional level, including, as applicable, through mutual recognition agreements. (page 15)

20. Each Party SHALL build and strengthen its country regulatory capacities and performance for timely approval of pandemic-related products and, in the event of a pandemic, accelerate the process of approving and licensing pandemic-related products for emergency use in a timely manner, including the sharing of regulatory dossiers with other institutions. (page 15)

21. ****The Parties SHALL, as appropriate, monitor and regulate against substandard and falsified pandemic-related products, through existing Member State mechanisms on substandard and falsified medical products. (page 15)

22. ****With a view to promoting greater sharing of knowledge and transparency, each Party, when providing public funding for research and development for pandemic prevention, preparedness, response and recovery of health systems, taking into account the extent of the public funding received, SHALL: (a) promote the free, public dissemination of the results of publicly and government-funded research for the development of pandemic-related products; (page 15)

23. ****With a view to promoting greater sharing of knowledge and transparency, each Party, when providing public funding for research and development for pandemic prevention, preparedness, response and recovery of health systems, taking into account the extent of the public funding received, SHALL: (b) endeavour to include terms and conditions on prices of products, allocation, data sharing and transfer of technology, as appropriate, and publication of contract terms; (page 15)

24. ****With a view to promoting greater sharing of knowledge and transparency, each Party, when providing public funding for research and development for pandemic prevention, preparedness, response and recovery of health systems, taking into account the extent of the public funding received, SHALL: (c) ensure that promoters of research for pandemic-related products assume an appropriate level of the associated risk; (page 16)

25. With a view to promoting greater sharing of knowledge and transparency, each Party, when providing public funding for research and development for pandemic prevention, preparedness, response and recovery of health systems, taking into account the extent of the public funding received, SHALL: (d) promote and incentivize technology co-creation and joint venture initiatives; and (page 16)

26. With a view to promoting greater sharing of knowledge and transparency, each Party, when providing public funding for research and development for pandemic prevention, preparedness, response and recovery of health systems, taking into account the extent of the public funding received, SHALL: (e) establish appropriate conditions for publicly funded research and development, including on distributed manufacturing, licensing, technology transfer and pricing policies. (page 16)

27. *****Parties SHALL increase the transparency of information about funding for research and development for pandemic-related products by: (a) disclosing information on public funding for research and development of potential pandemic-related products and provisions to enhance the availability and accessibility of the resulting work, including freely available and publicly accessible publications and public reporting of the relevant patents; (page 16)

28. *****Parties SHALL increase the transparency of information about funding for research and development for pandemic-related products by: (b) making it compulsory for manufacturers that receive public funding for the production of pandemic-related products to disclose prices and contractual terms for public procurement in times of pandemics, taking into account the extent of the public funding received; (page 16)

29. *****Parties SHALL increase the transparency of information about funding for research and development for pandemic-related products by: (c) encouraging manufacturers that receive other funds, external to the manufacturer, for the production of pandemic-related products to disclose prices and contractual terms for public procurement in times of pandemics. (page 16)

30. *****The Parties SHALL establish, no later than XX, with reference to existing models, a global compensation mechanism for injuries resulting from pandemic vaccines. (page 16)

31. *****Pending establishment of such global compensation mechanism, each Party SHALL, in contracts for the supply or purchase of pandemic-related products, ENDEAVOUR TO exclude buyer/recipient indemnity clauses of indefinite or excessive duration. (page 16)

32. *****In the conclusion of contracts for the supply or purchase of pandemic-related products, each Party SHALL ENDEAVOUR TO exclude confidentiality provisions that serve to limit disclosure of terms and conditions. (page 16)

33. Each Party SHALL, AS APPLICABLE, implement and apply international standards for, oversight of and reporting on laboratories and research facilities that carry out work to genetically alter organisms to increase their pathogenicity and transmissibility, in order to prevent accidental release of these pathogens, while ensuring that these measures do not create any unnecessary administrative hurdles for research. (page 16)

34. The Parties acknowledge the need to take steps, individually and collectively, to develop strong, resilient national, regional and international clinical research ecosystems. In that regard, the Parties, as appropriate, COMMIT to: (a) fostering and coordinating clinical research and clinical trials, including, as appropriate, through existing coordination mechanisms; (page 17)

35. The Parties acknowledge the need to take steps, individually and collectively, to develop strong, resilient national, regional and international clinical research ecosystems. In that regard, the Parties, as appropriate, COMMIT to: (b) ensuring equitable access to resources (funding or in-kind), clinical research and clinical trials, so that resources are deployed optimally and efficiently; (page 17)

36. *****The Parties acknowledge the need to take steps, individually and collectively, to develop strong, resilient national, regional and international clinical research ecosystems. In that regard, the Parties, as appropriate, COMMIT to: (c) supporting transparent and rapid reporting of clinical research and clinical trial results, to ensure evidence is available in a timely manner to inform national, regional and international decision-making; (page 17)

37. *****The Parties acknowledge the need to take steps, individually and collectively, to develop strong, resilient national, regional and international clinical research ecosystems. In that regard, the Parties, as appropriate, COMMIT to: (d) disclosing disaggregated information, for instance by gender and age, to the extent possible and as appropriate, on the results of clinical research and clinical trials relating to pandemic prevention, preparedness, response and recovery. (page 17)

38. The terms of the Pathogen Access and Benefit-Sharing System (PABS) System SHALL be developed no later than XX with a view to their provisional application consistent with Article 35 hereof. (page 17)

39. The PABS System SHALL cover all pathogens with pandemic potential, including their genomic sequences, as well as access to benefits arising therefrom, and ensure that it operates synergistically with other relevant access and benefit-sharing instruments. (page 17)

40. (a) Each Party, through its relevant and authorized laboratories, SHALL, in a rapid, systematic and timely manner: (i) provide pathogens with pandemic potential from early infections due to pathogens with pandemic potential or subsequent variants to a laboratory recognized or designated as part of an established WHO coordinated laboratory network; (page 17)

41. (a) Each Party, through its relevant and authorized laboratories, SHALL, in a rapid, systematic and timely manner: (ii) upload the genomic sequence of such pathogens with pandemic potential to one or more publicly accessible databases of its choice. For purposes hereof, “rapid” SHALL be understood to mean within XX hours from the time of identification of a pathogen with pandemic potential; (page 17)

42. (c) Access SHALL be accorded expeditiously by the laboratory recognized or designated as part of an established WHO coordinated laboratory network, subject to conclusion of a Standard Material Transfer Agreement, developed for the purposes of the PABS System, with the recipient in accordance with subsection (i) below. Any such access SHALL be subject to applicable biosafety and biosecurity rules and standards, and free of charge, or, when a fee is charged, it SHALL NOT exceed the minimal cost involved; (page 18)

43. Recipients of materials SHALL NOT claim any intellectual property or other rights that limit the facilitated access to pathogens with pandemic potential, or their genomic sequences or components, in the form received; (page 18)

44. (e) Access to pathogens with pandemic potential protected by intellectual and other property rights SHALL be consistent with relevant international agreements and with relevant national laws. (page 18)

45. (f) The Parties agree that benefits arising from facilitating access to pathogens with pandemic potential SHALL be shared fairly and equitably in accordance with the provisions of the PABS System. Accordingly, it is understood that production of pandemic vaccines or other pandemic related products, irrespective of the technology, information or material used, implies use of pathogens with pandemic potential, including the genomic sequence; (page 18)

46. (g) Facilitated access SHALL be provided pursuant to a Standard Material Transfer Agreement, the form of which SHALL be set out in the PABS System and that shall contain the benefit-sharing options available to entities accessing pathogens with pandemic potential; (page 18)

47. (h) Such options SHALL include, but not be limited to: (i) real-time access by WHO to 20% of the production of safe, efficacious and effective pandemic-related products, including diagnostics, vaccines, personal protective equipment and therapeutics, to enable equitable distribution, in particular to developing countries, according to public health risk and need and national plans that identify priority populations. (page 18)

48. The pandemic-related products SHALL be provided to WHO on the following basis: 10% as a donation and 10% at affordable prices to WHO; (ii) commitments by the countries where manufacturing facilities are located that they WILL facilitate the shipment to WHO of these pandemic-related products by the manufacturers within their jurisdiction, according to schedules to be agreed between WHO and manufacturers. (page 18)

49. (j) Upon adoption, each Party SHALL, in accordance with its national law, adopt and implement effective legislative, executive, administrative or other measures to give effect to such recognition at the domestic level and/or with respect to its relations with all other States and regional economic integration organizations, as appropriate; (page 18)

50. (k) The Parties SHALL support the further development and operationalization of the PABS System, including appropriate governance mechanisms, and participate in its operation, including through sustaining it in inter-pandemic times as well as appropriate scale-up in the event of a pandemic. (pages 18-19)

51. The Parties, working through the Governing Body for the WHO CA+, SHALL develop and finalize additional elements and tools necessary to fully implement, operationalize and sustain the PABS System, no later than XX. (page 19)

52. The Parties are encouraged to enhance financial, technical and technological support, assistance and cooperation, in particular to developing countries, to strengthen health emergency prevention and preparedness consistent with the goal of universal health coverage. The Parties SHALL strive to accelerate the achievement of universal health coverage. (page 19)

53. Each Party SHALL, in accordance with national law, adopt policies and strategies, supported by implementation plans, across the public and private sectors and relevant agencies, consistent with relevant tools, including, but not limited to, the International Health Regulations, and strengthen and reinforce public health functions for: (a) continued provision of quality routine and essential health services during pandemics, including clinical and mental health care and immunization, with a focus on primary health care and community-level interventions, and management of the backlog of and waiting lists for the diagnosis and treatment of, and interventions for, other illnesses, including care for patients with long-term effects from the pandemic disease; (page 19)

54. Each Party SHALL, in accordance with national law, adopt policies and strategies, supported by implementation plans, across the public and private sectors and relevant agencies, consistent with relevant tools, including, but not limited to, the International Health Regulations, and strengthen and reinforce public health functions for: (b) strengthening human resource capacities during inter-pandemic times and during pandemics;

55. Each Party SHALL, in accordance with national law, adopt policies and strategies, supported by implementation plans, across the public and private sectors and relevant agencies, consistent with relevant tools, including, but not limited to, the International Health Regulations, and strengthen and reinforce public health functions for: (c) surveillance (including using a One Health approach), outbreak investigation and control, through interoperable early warning and alert systems; (page 19)

56. Each Party SHALL, in accordance with national law, adopt policies and strategies, supported by implementation plans, across the public and private sectors and relevant agencies, consistent with relevant tools, including, but not limited to, the International Health Regulations, and strengthen and reinforce public health functions for: (d) sustained laboratory capacity for genomic sequencing, as well as for analysing and sharing such information; (page 19)

57. Each Party SHALL, in accordance with national law, adopt policies and strategies, supported by implementation plans, across the public and private sectors and relevant agencies, consistent with relevant tools, including, but not limited to, the International Health Regulations, and strengthen and reinforce public health functions for: (e) prevention of epidemic-prone diseases, and emerging, growing or evolving public health threats with pandemic potential, notably at the human-animal-environment interface; (page 19)

58. Each Party SHALL, in accordance with national law, adopt policies and strategies, supported by implementation plans, across the public and private sectors and relevant agencies, consistent with relevant tools, including, but not limited to, the International Health Regulations, and strengthen and reinforce public health functions for: (f) post-emergency health system recovery strategies; (page 19)

59. Each Party SHALL, in accordance with national law, adopt policies and strategies, supported by implementation plans, across the public and private sectors and relevant agencies, consistent with relevant tools, including, but not limited to, the International Health Regulations, and strengthen and reinforce public health functions for: (g) strengthening public health laboratory and diagnostic capacities, and national, regional and global networks, including standards and protocols for infection prevention and control, and public health laboratory biosafety and biosecurity; (page 20)

60. Each Party SHALL, in accordance with national law, adopt policies and strategies, supported by implementation plans, across the public and private sectors and relevant agencies, consistent with relevant tools, including, but not limited to, the International Health Regulations, and strengthen and reinforce public health functions for: (h) creating and maintaining up-to-date, universal platforms and technologies for forecasting and timely information sharing, through appropriate capacities, including building digital health and data science capacities. (page 20)

61. Each Party SHALL take the necessary steps to safeguard, protect, invest in and sustain a skilled, trained, competent and committed health and care workforce, at all levels, in a gender-responsive manner, with due protection of its employment, civil and human rights and well-being, consistent with international obligations and relevant codes of practice, with the aim of increasing and sustaining capacities for pandemic prevention, preparedness and response, while maintaining essential health services. This includes, subject to national law: (a) strengthening in- and post-service training, deployment, remuneration, distribution and retention of the health and care workforce, including community health workers and volunteers; (page 20)

62. Each Party SHALL take the necessary steps to safeguard, protect, invest in and sustain a skilled, trained, competent and committed health and care workforce, at all levels, in a gender-responsive manner, with due protection of its employment, civil and human rights and well-being, consistent with international obligations and relevant codes of practice, with the aim of increasing and sustaining capacities for pandemic prevention, preparedness and response, while maintaining essential health services. This includes, subject to national law: (b) addressing gender disparities and inequalities within the health and care workforce, to ensure meaningful representation, engagement, participation and empowerment of all health and care workers, while addressing discrimination, stigma and inequality and eliminating bias, including unequal remuneration, and noting that women still often face significant barriers to taking leadership and decision-making roles. (page 20)

63. The Parties SHALL invest in establishing, sustaining, coordinating and mobilizing an available, skilled and trained global public health emergency workforce that is deployable to support Parties upon request, based on public health need, in order to contain outbreaks and prevent an escalation of small scale spread to global proportions. (page 20)

64. The Parties WILL support the development of a network of training institutions, national and regional facilities and centres of expertise in order to establish common guidance to enable more predictable, standardized, timely and systematic response missions and deployment of the aforementioned public health emergency workforce. (page 20)

65. Each Party SHALL undertake regular and systematic capacity assessments in order to identify capacity gaps and develop and implement comprehensive, inclusive, multi-sectoral national plans and strategies for pandemic prevention, preparedness and response, based on relevant tools developed by WHO. (page 20)

66. Each Party SHALL periodically assess the functioning, readiness and gaps of its preparedness and multi-sectoral response, logistics and supply chain management, through appropriate simulation or tabletop exercises, that include risk and vulnerability mapping. Such exercises may consist of after-action reviews of actual public health emergencies that can support identifying gaps, share lessons learned and improve national pandemic prevention, preparedness and response. (pages 20-21)

67. The Parties WILL convene multi-country or regional tabletop exercises every two years, with technical support from the WHO Secretariat, with an aim to identify gaps in multi-country response capacity. (page 21)

68. Each Party SHALL provide annual (or biennial) reporting, building on existing relevant reporting where possible, on its pandemic prevention, preparedness, response and health systems recovery capacities. (page 21)

69. The Parties SHALL develop and implement a transparent, effective and efficient pandemic prevention, preparedness and response monitoring and evaluation system, which includes targets and national and global standardized indicators, with necessary funding for developing countries for this purpose. (page 21)

70. The Parties SHALL endeavour to implement the recommendations generated from review mechanisms, including prioritization of activities for immediate action. (page 21)

71. The Parties SHALL, in accordance with their national laws, incorporate non-discriminatory measures to protect human rights as part of their pandemic prevention, preparedness, response and recovery, with a particular emphasis on the rights of persons in vulnerable situations. (page 21)

72. [AAAARRRRRRGGGGGHHHHHH!!!!!! This is a massive perversion of the concept of unalienable rights!] Each Party SHALL: (a) incorporate into its laws and policies human rights protections during public health emergencies, including, but not limited to, requirements that any limitations on human rights are aligned with international law, including by ensuring that: (i) any restrictions are nondiscriminatory, necessary to achieve the public health goal and the least restrictive necessary to protect the health of people; (ii) all protections of rights, including but not limited to, provision of health services and social protection programmes, are non-discriminatory and take into account the needs of people at high risk and persons in vulnerable situations; and (iii) people living under any restrictions on the freedom of movement, such as quarantines and isolations, have sufficient access to medication, health services and other necessities and rights; (page 21)

73. *****Each Party SHALL: (b) endeavour to develop an independent and inclusive advisory committee to advise the government on human rights protections during public health emergencies, including on the development and implementation of its legal and policy framework, and any other measures that may be needed to protect human rights. (page 21)

74. The Parties recognize the need to coordinate, collaborate and cooperate, in the spirit of international solidarity, with competent international and regional intergovernmental organizations and other bodies in the formulation of cost-effective measures, procedures and guidelines for pandemic prevention, preparedness, response and recovery of health systems, and to this end [the Parties] SHALL: (a) promote global, regional and national political commitment, coordination and leadership for pandemic prevention, preparedness, response and recovery by means that include establishing appropriate governance arrangements; (page 22)

75. The Parties recognize the need to coordinate, collaborate and cooperate, in the spirit of international solidarity, with competent international and regional intergovernmental organizations and other bodies in the formulation of cost-effective measures, procedures and guidelines for pandemic prevention, preparedness, response and recovery of health systems, and to this end [the Parties] SHALL: (b) support mechanisms that ensure global, regional and national policy decisions are science and evidence-based; (page 22)

76. The Parties recognize the need to coordinate, collaborate and cooperate, in the spirit of international solidarity, with competent international and regional intergovernmental organizations and other bodies in the formulation of cost-effective measures, procedures and guidelines for pandemic prevention, preparedness, response and recovery of health systems, and to this end [the Parties] SHALL: (c) develop, as necessary, and implement global policies that recognize the specific needs, and ensure the protection of, persons in vulnerable situations, indigenous peoples, and those living in fragile environments or areas, such as Small Island Developing States, who face multiple threats simultaneously, by gathering and analysing data, including data disaggregated by gender, to show the impact of policies on different groups; (page 22)

77. The Parties recognize the need to coordinate, collaborate and cooperate, in the spirit of international solidarity, with competent international and regional intergovernmental organizations and other bodies in the formulation of cost-effective measures, procedures and guidelines for pandemic prevention, preparedness, response and recovery of health systems, and to this end [the Parties] SHALL: (d) promote equitable gender, geographical and socioeconomic status, representation and participation, as well as the participation of youth and women, in global and regional decision making processes, global networks and technical advisory groups; (page 22)

78. *****The Parties recognize the need to coordinate, collaborate and cooperate, in the spirit of international solidarity, with competent international and regional intergovernmental organizations and other bodies in the formulation of cost-effective measures, procedures and guidelines for pandemic prevention, preparedness, response and recovery of health systems, and to this end [the Parties] SHALL: (e) ensure solidarity with, and prevent stigmatization of, countries that report public health emergencies, as an incentive to facilitate transparency and timely reporting and sharing of information; (page 22)

79. The Parties recognize the need to coordinate, collaborate and cooperate, in the spirit of international solidarity, with competent international and regional intergovernmental organizations and other bodies in the formulation of cost-effective measures, procedures and guidelines for pandemic prevention, preparedness, response and recovery of health systems, and to this end [the Parties] SHALL: (f) facilitate WHO with rapid access to outbreak areas within the Party’s jurisdiction or control, including through the deployment of rapid response and expert teams, to assess and support the response to emerging outbreaks. (page 22)

80. Each Party SHALL establish, implement and adequately finance an effective national coordinating multisectoral mechanism with meaningful representation, engagement and participation of communities. (page 23)

81. Each Party SHALL develop, in accordance with its national context, comprehensive national pandemic prevention, preparedness, response and recovery plans pre-, post- and inter-pandemic that, inter alia: (i) identify and prioritize populations for access to pandemic-related products and health services; (ii) support timely and scalable mobilization of multidisciplinary surge capacity of human and financial resources, and facilitate timely allocation of resources to the frontline pandemic response; (iii) review the status of stockpiles and surge capacity of essential public health and clinical resources, and surge capacity in production of pandemic-related products; (iv) facilitate rapid and equitable restoration of public health capacities following a pandemic; and (v) promote collaboration with non-State actors, the private sector and civil society. (page 23)

82. Each Party WILL take steps to address the social, environmental and economic determinants of health, and vulnerability conditions that contribute to the emergence and spread of pandemics, and prevent or mitigate the socioeconomic impacts of pandemics, including but not limited to, those affecting economic growth, the environment, employment, trade, transport, gender equality, education, social assistance, housing, food insecurity, nutrition and culture, and especially for persons in vulnerable situations. (page 23)

83. The Parties COMMIT to increase science, public health and pandemic literacy in the population, as well as access to information on pandemics and their effects, and tackle false, misleading, misinformation or disinformation, including through promotion of international cooperation. (page 23)

84. The Parties WILL contribute to research and inform policies on factors that hinder adherence to public health and social measures, confidence and uptake of vaccines, use of appropriate therapeutics and trust in science and government institutions. (page 24)

85. The Parties SHALL promote science and evidence-informed effective and timely risk assessment, including the uncertainty of data and evidence, when communicating such risk to the public. (page 24)

86. The Parties, with an aim of safeguarding human health and detecting and preventing health threats, SHALL promote and enhance synergies between multi-sectoral and trans-disciplinary collaboration at the national level and cooperation at the international level, in order to identify, conduct risk assessment of and share pathogens with pandemic potential at the interface between human, animal and environment ecosystems, while recognizing their interdependence. (page 24)

87. The Parties WILL identify and integrate into relevant pandemic prevention and preparedness plans interventions that address the drivers of the emergence and re-emergence of disease at the human-animal-environment interface, including but not limited to climate change, land use change, wildlife trade, desertification and antimicrobial resistance. (page 24)

88. The Parties COMMIT to regularly assess One Health capacities, insofar as they relate to pandemic prevention, preparedness, response and recovery of health systems, and to identify gaps, policies and the funding needed to strengthen those capacities. (page 24)

89. The Parties COMMIT to strengthen synergies with other existing relevant instruments that address the drivers of pandemics, such as climate change, biodiversity loss, ecosystem degradation and increased risks at the human-animal-environment interface due to human activities. (page 24)

90. The Parties COMMIT to strengthen multi-sectoral, coordinated, interoperable and integrated One Health surveillance systems and strengthen laboratory capacity to identify and assess the risks and emergence of pathogens and variants with pandemic potential, in order to minimize spill-over events, mutations and the risks associated with zoonotic neglected tropical and vector-borne diseases, with a view to preventing small-scale outbreaks in wildlife or domesticated animals from becoming a pandemic. (page 24)

91. Each Party SHALL: (a) implement actions to prevent pandemics from pathogens resistant to antimicrobial agents, taking into account relevant tools and guidelines, through a One Health approach, and collaborate with relevant partners, including the Quadripartite; (page 24)

92. Each Party SHALL: (b) foster actions at national and community levels that encompass whole-of-government and whole-of-society approaches to control zoonotic outbreaks (in wildlife and domesticated animals), including engagement of communities in surveillance that identifies zoonotic outbreaks and antimicrobial resistance at source; (page 24)

93. Each Party SHALL: (c) develop and implement a national One Health action plan on antimicrobial resistance that strengthens antimicrobial stewardship in the human and animal sectors, optimizes antimicrobial consumption, increases investment in, and promotes equitable and affordable access to, new medicines, diagnostic tools, vaccines and other interventions, strengthens infection prevention and control in health care settings and sanitation and biosecurity in livestock farms, and provides technical support to developing countries; (page 25)

94. Each Party SHALL: (d) enhance surveillance to identify and report on pathogens resistant to antimicrobial agents in humans, livestock and aquaculture that have pandemic potential, building on the existing global reporting systems; (page 25)

95. Each Party SHALL: (e) take the One Health approach into account at national, subnational and facility levels in order to produce science-based evidence, and support, facilitate and/or oversee the correct, evidence-based and risk-informed implementation of infection prevention and control. (page 25)

96. The Parties recognize the important role that financial resources play in achieving the objective of the WHO CA+ and the primary financial responsibility of national governments in protecting and promoting the health of their populations. In that regard, each Party SHALL: (a) cooperate with other Parties, within the means and resources at its disposal, to raise financial resources for effective implementation of the WHO CA+ through bilateral and multilateral funding mechanisms; (page 25)

97. The Parties recognize the important role that financial resources play in achieving the objective of the WHO CA+ and the primary financial responsibility of national governments in protecting and promoting the health of their populations. In that regard, each Party SHALL: (b) plan and provide adequate financial support in line with its national fiscal capacities for: (i) strengthening pandemic prevention, preparedness, response and recovery of health systems; (ii) implementing its national plans, programmes and priorities; and (iii) strengthening health systems and progressive realization of universal health coverage; (page 25)

98. The Parties recognize the important role that financial resources play in achieving the objective of the WHO CA+ and the primary financial responsibility of national governments in protecting and promoting the health of their populations. In that regard, each Party SHALL: (c) commit to prioritize and increase or maintain, including through greater collaboration between the health, finance and private sectors, as appropriate, domestic funding by allocating in its annual budgets not lower than 5% of its current health expenditure to pandemic prevention, preparedness, response and health systems recovery, notably for improving and sustaining relevant capacities and working to achieve universal health coverage; (page 25)

99. The Parties recognize the important role that financial resources play in achieving the objective of the WHO CA+ and the primary financial responsibility of national governments in protecting and promoting the health of their populations. In that regard, each Party SHALL: (d) commit to allocate, in accordance with its respective capacities, XX% of its gross domestic product for international cooperation and assistance on pandemic prevention, preparedness, response and health systems recovery, particularly for developing countries, including through international organizations and existing and new mechanisms. (page 25)

100. The Parties SHALL ensure, through innovative existing and/or new mechanisms, sustainable and predictable financing of global, regional and national systems, capacities, tools and global public goods, while avoiding duplication, promoting synergies and enhancing transparent and accountable governance of these mechanisms, to support strengthening pandemic prevention, preparedness, response and recovery of health systems, based on public health risk and need, particularly in developing countries. (page 25)

101. The Parties SHALL promote, as appropriate, the use of bilateral, regional, subregional and other appropriate and relevant channels to provide funding for the development and strengthening of pandemic prevention, preparedness, response and health system recovery programmes of developing country Parties. (page 26)

102. The Parties WILL facilitate rapid and effective mobilization of adequate financial resources, including from international financing facilities, to affected countries, based on public health need, to maintain and restore routine public health functions during and in the aftermath of a pandemic response. (page 26)

103. The Parties represented in relevant regional and international intergovernmental organizations and financial and development institutions SHALL encourage these entities to provide financial assistance for developing country Parties to support them in meeting their obligations under the WHO CA+, without limiting their participation in or membership of these organizations. (page 26)

104. Any Party that withdraws from the WHO CA+ SHALL not be considered as having also withdrawn from any protocol to which it is a Party, or from any related instrument, unless such a Party formally withdraws from such other instruments, and does so in accordance with the relevant terms, if any, thereof. (page 29)

105. Each Party to the WHO CA+ SHALL have one vote in the COP, except as provided for in paragraph 2 of this Article. (page 29)

I have been reporting on the proposed “Pandemic Treaty” for over a year.

Below are some of the articles that I have previously published.

by James Roguski

The old system is crumbling, and we must build its replacement quickly.

If you are fed up with the government, hospital, medical, pharmaceutical, media, industrial complex and would like to help build a holistic alternative to the WHO, then feel free to contact me directly anytime.

JamesRoguski.com

JamesRoguski.substack.com/about

JamesRoguski.substack.com/archive

310-619-3055

All content is free to all readers.

All support is deeply appreciated.

CLICK HERE TO DONATE